Antifungal drugs and rational use of antifungals in treating invasive aspergillosis: The role of the hospital pharmacist

Pharmacy World and Science

Volumn 27, Issue 1, 2005, Pages 31-34

  Bauters, Tiene G M ^a   Buyle, Franky M A ^a   Peleman, Renaat ^a   Robays, Hugo ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Antifungal agents; Aspergillosis; Formulary management; Guidelines; Hospital pharmacist

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN A; DIGOXIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; IMIDAZOLE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; LIPOSOME; MICAFUNGIN; NYSTATIN; POLYENE; POSACONAZOLE; PREDNISOLONE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TACROLIMUS; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ASPERGILLOSIS; CHILL; CLINICAL TRIAL; DATA BASE; DRUG EFFICACY; FEVER; HUMAN; HYPOXIA; MEDLINE; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PHARMACIST; PRACTICE GUIDELINE; REVIEW; RIGOR; UNIVERSITY HOSPITAL;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG UTILIZATION; HUMANS; MYCOSES; PHARMACY SERVICE, HOSPITAL; PRACTICE GUIDELINES;

EID: 14944378351     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-004-1735-0     Document Type: Review

References (28)

1. S Mossad 2003 Prevention and treatment of fungal infections in bone marrow transplantation. Curr Hematol Rep 2 302 9
2. Sanglard D, Bille J. Current understanding of the modes of action of and resistance mechanisms to conventional and emerging antifungal agents for treatment of Candida infections. In: Calderone R, editor. Washington, USA: ASM Press, 2002.
3. AH Groll TJ Walsh 2002 Antifungal chemotherapy: advances and perspectives. Swiss Med Weekly 132 303 11
4. Prevention, diagnosis and management of invasive aspergillosis in immunocompromised patients. The Infectious Diseases Advisory Board, 2004. ISBN 90-805936-4-8.
5. RD Meyer 1992 Current role of therapy with amphotericin B. Clin Infect Dis 14(Suppl.1) S154 S160
6. http://www.doctorfungus.org/thedrugs/Nystatin liposomal.htm.
7. CA Lyman TJ Walsh 1992 Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44 9 35
8. EJ Anaissie DP Kontonyiannis C Huls SE Vartivarian C Karl RA Prince J Bosso GP Bodey 1995 Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 172 599 602
9. J Wheat S MaWhinney R Hafner D McKinsey D Chen A Korzun 1997 National institute of allergy and infectious diseases acquired immunodeficiency syndrome clinical trials group and mycoses study group. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. Am J Med 103 223 32
10. PG Pappas RW Bradsher CA Kauffman GA Cloud CJ Thomas GD Campbell 1997 National institute of allergy and infectious diseases mycoses study group. Treatment of blastomycosis with higher doses of fluconazole. Clin Infect Dis 25 200 205
11. K Vandewoude D Vogelaers J Decruyenaere P Jaqmin K De Beule A Van Peer 1997 Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 41 2714 8
12. HH Zhou M Goldman J Wu R Woestenborghs AE Hassell P Lee 1998 A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol 38 593 602
13. DJ Sheehan CA Hitchcock CM Sibley 1999 Current and emerging azole antifungal agents. Clin Microbiol Rev 12 40 79
14. D Law CB Moore DW Denning 1997 Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother 41 2310 11
15. http://www.doctorfungus.org/thedrugs/Ravuconazole.htm.
16. FC Odds AJP Brown NAR Gow 2003 Antifungal agents: mechanisms of action. Trends Microbiol 11 272 79
17. D Denning 2002 Echinocandins: a new class of antifungals. J Antimicrob Chemother 49 889 91
18. D Denning 1997 Echinocandins and pneumocandins: a new antifungal class with a novel mode of action. J Antimicrob Chemoth 40 611 14
19. N Wiederhold R Lewis 2003 The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Drugs 12 1313 33
20. D Andes M van Ogtrop 2000 In vivo characterization of the pharmacodynamics of fIucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 44 938 42
21. https://www.inami.fgov.be/.
22. GA Wetzstein 2000 Intravenous to oral (IV:PO) anti-infective conversion therapy. Cancer Control 7 170 6
23. D Nathwani G Tillotson P Davey 1997 Sequential antimicrobial therapy, the role of quinolones. J Antimicrob Chemother 39 441 6
24. V Von Gunten V Amos A Sidler J Beney N Troillet J Reymond 2003 Hospital pharmacists' reinforcement of guidelines for switching from parenteral to oral antibiotics: a pilot study. Pharm World Sci 25 2 52 5
25. HM Lazarus JL Blumer S Yanovich H Schlamm A Romero 2002 Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 42 4 395 402
26. RB Laing AR Mackenzie H Shaw IM Gould JG Douglas 1998 The effect of intravenous-to-oral switch guidelines on the use of parenteral on use antimicrobials in medical wards. J Antimicrob Chemother 42 107 11
27. A Somers T Bauters H Robays M Bogaert F Colardyn 2002 Evaluation of human albumin use in a university hospital in Belgium. Pharm World Sci 24 3 111 6
28. D Nathwani K Gray H Borland 2002 Quality indicators for antibiotic control programmes. J Hosp Infect 50 165 9